MedTrace Logo

IMPT Dose Escalation for NSCLC (HyDose)

NCT06484491 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2026-01-30

No results posted yet for this study

Summary

The goal of this clinical pilot trial is to learn if dose to the tumor in the lung can be safely increased using proton therapy in stage III non-small-cell lung cancer patients receiving combined chemotherapy and radiotherapy. The main questions it aims to answer are:

* Is the risk of severe radiotherapy toxicities (requiring hospital admission) within acceptable margins ?
* What is a rough estimate of the effect of the treatment under study?

Compared to standard care in our clinic, all participants in this pilot trial will

* Receive a higher dose of proton therapy to the tumor in the lung albeit with the same number of radiotherapy visits as the current standard treatment.
* Receive two additional follow-up visits at the clinic after treatment, namely 4 and 6 weeks after finishing radiotherapy.
* Two additional blood withdrawals at the last week of radiotherapy and 4 weeks after finishing radiotherapy, to measure a type of white blood cells.
* Receive an extra quality of life questionnaire at the last week of radiotherapy.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

RADIATION

Dose-escalated intensity-modulated proton therapy (IMPT-74)

Heterogeneous simultaneous integrated boost of 74.0 Gy (RBE) to primary tumor \>15mm away form mediastinal envelope, and 64.0 Gy (RBE) to primary tumor =\< 15mm away from mediastinal envelope. The rest of the clinical target volume, including affected lymph nodes, receives 60.0 Gy (RBE).

DRUG

Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy

Induction course: -Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2). Concurrent chemoradiotherapy: * Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays. * Radiotherapy will be given for 5x5 days.

DRUG

Immunotherapy: adjuvant durvalumab

Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy. Doses: * Start durvalumab 10 mg/kg 1x/14 days. * If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk. * Continue for 12 months in total.

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • R. Wijsman, MD PhD · University Medical Center Groningen

  • A. Van der Wekken, MD PhD · University Medical Center Groningen

  • E. Korevaar, dr ir (PhD) · University Medical Center Groningen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-10-01
Completion
2028-10-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06484491 on ClinicalTrials.gov